Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Kidney Diseases and Covid-19 Infection: Causes and Effect, Supportive Therapeutics and Nutritional Perspectives Publisher



Askari H1 ; Sanadgol N2, 3 ; Azarnezhad A4 ; Tajbakhsh A5 ; Rafiei H6 ; Safarpour AR1 ; Gheibihayat SM7 ; Raeisabdollahi E8 ; Savardashtaki A5, 9 ; Ghanbariasad A10, 11 ; Omidifar N12
Authors

Source: Heliyon Published:2021


Abstract

Recently, the novel coronavirus disease 2019 (COVID-19), has attracted the attention of scientists where it has a high mortality rate among older adults and individuals suffering from chronic diseases, such as chronic kidney diseases (CKD). It is important to elucidate molecular mechanisms by which COVID-19 affects the kidneys and accordingly develop proper nutritional and pharmacological strategies. Although numerous studies have recently recommended several approaches for the management of COVID-19 in CKD, its impact on patients with renal diseases remains the biggest challenge worldwide. In this paper, we review the most recent evidence regarding causality, potential nutritional supplements, therapeutic options, and management of COVID-19 infection in vulnerable individuals and patients with CKD. To date, there is no effective treatment for COVID-19-induced kidney dysfunction, and current treatments are yet limited to anti-inflammatory (e.g. ibuprofen) and anti-viral medications (e.g. Remdesivir, and Chloroquine/Hydroxychloroquine) that may increase the chance of treatment. In conclusion, the knowledge about kidney damage in COVID-19 is very limited, and this review improves our ability to introduce novel approaches for future clinical trials for this contiguous disease. © 2021
Other Related Docs
11. The Prophylaxis and Treatment Potential of Supplements for Covid-19, European Journal of Pharmacology (2020)
16. The Biochemical Parameters and Vitamin D Levels in Icu Patients With Covid-19: A Cross-Sectional Study, Endocrine# Metabolic and Immune Disorders - Drug Targets (2021)